We are live on ! Find out more
TRIB

Trinity Biotech

70 hedge funds and large institutions have $251M invested in Trinity Biotech in 2013 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 23 increasing their positions, 24 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 8

50% more call options, than puts

Call options by funds: $614K | Put options by funds: $409K

32% more capital invested

Capital invested by funds: $191M → $251M (+$60.4M)

9% more funds holding

Funds holding: 6470 (+6)

0% more funds holding in top 10

Funds holding in top 10: 44 (0)

4% less repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 24

Holders
70
Holders Change
+6
Holders Change %
+9.38%
% of All Funds
2.27%
Holding in Top 10
4
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.13%
New
15
Increased
23
Reduced
24
Closed
8
Calls
$614K
Puts
$409K
Net Calls
+$205K
Net Calls Change
+$373K
Name Holding Trade Value Shares
Change
Change in
Stake
DWA
76
Dorsey Wright & Associates
California
-$108K -1,284 Closed
Asset Management One
77
Asset Management One
Japan
-$79K -940 Closed

TRIB Hedge Fund Activity: Q3 2013 in Review

70 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2013, worth a combined $251M — up 32% from $191M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new TRIB positions and 8 closed out — a net gain of 7 holders — while 23 added to existing stakes and 24 trimmed.

The largest buyer was Cardinal Capital Management LLC (Connecticut), adding an estimated $4.26M. The largest seller was Heartland Advisors, cutting an estimated $6.23M.

  • 70 institutional investors held Trinity Biotech (TRIB) as of Q3 2013, up from 64 in Q2 2013.
  • Funds reported $251M of Trinity Biotech stock for Q3 2013, up 32% quarter-over-quarter.
  • 15 funds opened new Trinity Biotech positions in Q3 2013 and 8 closed out, a net change of +7 holders.
  • The largest Trinity Biotech buyer in Q3 2013 was Cardinal Capital Management LLC (Connecticut), an estimated $4.26M added.
  • The largest Trinity Biotech seller in Q3 2013 was Heartland Advisors, an estimated $6.23M sold.

Based on aggregated 13F filings for Q3 2013.